<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JDR</journal-id>
<journal-id journal-id-type="hwp">spjdr</journal-id>
<journal-id journal-id-type="nlm-ta">J Dent Res</journal-id>
<journal-title>Journal of Dental Research</journal-title>
<issn pub-type="ppub">0022-0345</issn>
<issn pub-type="epub">1544-0591</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0022034513490732</article-id>
<article-id pub-id-type="publisher-id">10.1177_0022034513490732</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
<subj-group subj-group-type="heading">
<subject>Biological</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Immune Therapeutic Potential of Stem Cells from Human Supernumerary Teeth</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Makino</surname><given-names>Y.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034513490732">1</xref>
<xref ref-type="aff" rid="aff2-0022034513490732">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamaza</surname><given-names>H.</given-names></name>
<xref ref-type="aff" rid="aff3-0022034513490732">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Akiyama</surname><given-names>K.</given-names></name>
<xref ref-type="aff" rid="aff4-0022034513490732">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ma</surname><given-names>L.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034513490732">1</xref>
<xref ref-type="aff" rid="aff3-0022034513490732">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hoshino</surname><given-names>Y.</given-names></name>
<xref ref-type="aff" rid="aff3-0022034513490732">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nonaka</surname><given-names>K.</given-names></name>
<xref ref-type="aff" rid="aff3-0022034513490732">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Terada</surname><given-names>Y.</given-names></name>
<xref ref-type="aff" rid="aff2-0022034513490732">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kukita</surname><given-names>T.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034513490732">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shi</surname><given-names>S.</given-names></name>
<xref ref-type="aff" rid="aff4-0022034513490732">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamaza</surname><given-names>T.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034513490732">1</xref>
<xref ref-type="corresp" rid="corresp1-0022034513490732">*</xref>
</contrib>
</contrib-group>
<aff id="aff1-0022034513490732"><label>1</label>Department of Molecular Cell Biology and Oral Anatomy, Kyushu University Graduate School of Dental Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan</aff>
<aff id="aff2-0022034513490732"><label>2</label>Department of Fixed Prosthodontics, Kyushu University Graduate School of Dental Science, Fukuoka, Japan</aff>
<aff id="aff3-0022034513490732"><label>3</label>Department of Pediatric Dentistry, Kyushu University Graduate School of Dental Science, Fukuoka, Japan</aff>
<aff id="aff4-0022034513490732"><label>4</label>Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry of USC, University of Southern California, CA, USA</aff>
<author-notes><corresp id="corresp1-0022034513490732"><label>*</label><email>yamazata@dent.kyushu-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>92</volume>
<issue>7</issue>
<fpage>609</fpage>
<lpage>615</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>4</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>4</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>Â© International &amp; American Associations for Dental Research</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">International &amp; American Associations for Dental Research</copyright-holder>
</permissions>
<abstract>
<p>Discoveries of immunomodulatory functions in mesenchymal stem cells (MSCs) have suggested that they might have therapeutic utility in treating immune diseases. Recently, a novel MSC population was identified from dental pulp of human supernumerary teeth, and its multipotency characterized. Herein, we first examined the <italic>in vitro</italic> and <italic>in vivo</italic> immunomodulatory functions of human supernumerary tooth-derived stem cells (SNTSCs). SNTSCs suppressed not only the viability of T-cells, but also the differentiation of interleukin 17 (IL-17)-secreting helper T (Th17) -cells in <italic>in vitro</italic> co-culture experiments. In addition, systemic SNTSC transplantation ameliorated the shortened lifespan and elevated serum autoantibodies and nephritis-like renal dysfunction in systemic lupus erythematosus (SLE) model MRL/<italic>lpr</italic> mice. SNTSC transplantation also suppressed <italic>in vivo</italic> increased levels of peripheral Th17 cells and IL-17, as well as <italic>ex vivo</italic> differentiation of Th17 cells in MRL/<italic>lpr</italic> mice. Adoptive transfer experiments demonstrated that SNTSC-transplanted MRL/<italic>lpr</italic> mouse-derived T-cell-adopted immunocompromised mice showed a longer lifespan in comparison with non-transplanted MRL/<italic>lpr</italic> mouse-derived T-cell-adopted immunocompromised mice, indicating that SNTSC transplantation suppresses the hyper-immune condition of MRL/<italic>lpr</italic> mice through suppressing T-cells. Analysis of these data suggests that SNTSCs are a promising MSC source for cell-based therapy for immune diseases such as SLE.</p>
</abstract>
<kwd-group>
<kwd>supernumerary teeth</kwd>
<kwd>dental pulp</kwd>
<kwd>mesenchymal stem cells</kwd>
<kwd>T-cells</kwd>
<kwd>immunotherapy</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0022034513490732" sec-type="intro">
<title>Introduction</title>
<p>Immunomodulatory functions of human mesenchymal stem cells (MSCs), which are capable of differentiating into multi-lineage cells (<xref ref-type="bibr" rid="bibr1-0022034513490732">Bianco <italic>et al</italic>., 2001</xref>), have been discovered against a variety of immune cells such as T- and B-lymphocytes and dendritic cells (<xref ref-type="bibr" rid="bibr2-0022034513490732">Corcione <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="bibr18-0022034513490732">Spaggiari <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="bibr15-0022034513490732">Ramasamy <italic>et al</italic>., 2007</xref>) and have offered MSC-based cell therapy to several immune diseases such as acute graft-<italic>vs</italic>.-host-disease (GVHD; <xref ref-type="bibr" rid="bibr11-0022034513490732">Le Blanc <italic>et al</italic>., 2004</xref>) and systemic lupus erythematosus (SLE; <xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>). Human oral tissues serve a variety of unique MSC populations such as dental pulp stem cells, stem cells from human exfoliated deciduous teeth (SHED), periodontal ligament stem cells, stem cells from root apical papilla, and gingival stem cells (<xref ref-type="bibr" rid="bibr7-0022034513490732">Gronthos <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="bibr13-0022034513490732">Miura <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="bibr16-0022034513490732">Seo <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="bibr17-0022034513490732">Sonoyama <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="bibr27-0022034513490732">Zhang <italic>et al</italic>., 2009</xref>). These oral MSCs also express an immunosuppressive capacity to T-cells (<xref ref-type="bibr" rid="bibr23-0022034513490732">Wada <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr27-0022034513490732">Zhang <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>; <xref ref-type="bibr" rid="bibr28-0022034513490732">Zhao <italic>et al</italic>., 2012</xref>) and provide a possible treatment for immune diseases (<xref ref-type="bibr" rid="bibr27-0022034513490732">Zhang <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>; <xref ref-type="bibr" rid="bibr28-0022034513490732">Zhao <italic>et al</italic>., 2012</xref>).</p>
<p>Recently, a new MSC population has been identified from the dental pulp of human supernumerary teeth, and its capability for colony formation and multi-differentiation has been characterized (<xref ref-type="bibr" rid="bibr9-0022034513490732">Huang <italic>et al</italic>., 2008</xref>). However, no one has evaluated whether the supernumerary tooth-derived stem cells (SNTSCs) possess an immunomodulatory capacity and offer therapeutic efficacy for immune diseases. In this study, we examined an <italic>in vitro</italic> immunoregulatory property of SNTSCs for T-cells and show an <italic>in vivo</italic> immune effect of SNTSCs in human SLE model MRL/<italic>lpr</italic> mice.</p>
</sec>
<sec id="section2-0022034513490732" sec-type="materials|methods">
<title>Materials &amp; Methods</title>
<sec id="section3-0022034513490732">
<title>Source of Supernumerary Teeth</title>
<p>Human maxillary supernumerary teeth, mesiodens, were obtained as clinically discarded biological samples from five patients (from 5 to 7 yrs old) with their parentsâ informed consent at the Department of Pediatric Dentistry of Kyushu University Hospital, according to approved Institutional Review Board guidelines (Kyushu University, Protocol number: 393-01).</p>
</sec>
<sec id="section4-0022034513490732">
<title>Antibodies and Reagents</title>
<p>All antibodies and reagents used in this study are described in the Appendix.</p>
</sec>
<sec id="section5-0022034513490732">
<title>Mice</title>
<p>Immunocompromised NOD SCID mice (female, 8-week-old) were purchased from CLEA Japan, Inc. (Tokyo, Japan). C57BL/6 and C57BL/6J-<italic>lpr/lpr</italic> (MRL/<italic>lpr</italic>) mice (female, 8-week-old) were obtained from Japan SLC, Inc. (Shizuoka, Japan). All animal experiments were performed under an institutionally approved protocol for the care and use of laboratory animals (Kyushu University, Protocol number: A21-044-1).</p>
</sec>
<sec id="section6-0022034513490732">
<title>Culture of SNTSCs and hBMMSCs</title>
<p>SNTSCs isolated from the dental pulp tissues of supernumerary teeth were cultured as described previously (<xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>) and as in the Appendix. hBMMSC were isolated as described previously (<xref ref-type="bibr" rid="bibr25-0022034513490732">Yamaza <italic>et al</italic>., 2009</xref>) and cultured as in the Appendix.</p>
</sec>
<sec id="section7-0022034513490732">
<title><italic>In vitro</italic> Immunomodulatory Assay</title>
<sec id="section8-0022034513490732">
<title>T-cell Survival Assay</title>
<p>SNTSCs or hBMMSCs were co-cultured with phytohemagglutinin (PHA)- or anti-human CD3 antibody-activated human peripheral blood mononuclear cells (PBMNCs) as described in the Appendix. The cell viability and apoptosis of T-cells were analyzed as described in the Appendix.</p>
</sec>
<sec id="section9-0022034513490732">
<title>Induction of Interleukin 17 (IL-17)-secreting Helper T (Th17) -cells and Regulatory T-cells (Tregs)</title>
<p>Induction and analysis of Th17 cells and Tregs co-cultured with SNTSCs or hBMMSCs are described in the Appendix.</p>
</sec>
</sec>
<sec id="section10-0022034513490732">
<title>Assay of SNTSC-treated MRL/lpr Mice</title>
<p>Cultured SNTSCs or hBMMSCs (0.1 x 10<sup>6</sup>/10 g body weight/100 ÂµL PBS) were intravenously transplanted into MRL/<italic>lpr</italic> mice at the age of 16 wks as described previously (<xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>). The therapeutic efficacy on the mice was assessed as described in the Appendix.</p>
</sec>
<sec id="section11-0022034513490732">
<title><italic>In vivo</italic> Tracing of SNTSCs</title>
<p>The distribution of transplanted SNTSCs into MRL/lpr mice was assayed as described previously (<xref ref-type="bibr" rid="bibr12-0022034513490732">Ma <italic>et al</italic>., 2012</xref>) and as in the Appendix.</p>
</sec>
<sec id="section12-0022034513490732">
<title>Culture and Cell Viability Assay of Mouse PanT-cells</title>
<p>PanT-cells from mouse spleen were cultured and assayed as in the Appendix.</p>
</sec>
<sec id="section13-0022034513490732">
<title>Adoptive Transfer of Mouse PanT-cells into SCID Mice</title>
<p>Mouse PanT-cells (10 x 10<sup>6</sup>/mouse/100 ÂµL PBS) were intravenously infused into SCID mice and their survival assayed as described in the Appendix.</p>
</sec>
<sec id="section14-0022034513490732">
<title>Statistical Analysis</title>
<p>Data were assayed by a one-way ANOVA F test. <italic>P</italic> values less than .05 were considered significant.</p>
</sec>
</sec>
<sec id="section15-0022034513490732" sec-type="results">
<title>Results</title>
<sec id="section16-0022034513490732">
<title>SNTSCs Display MSC Properties</title>
<p>Cells isolated from the dental pulp of supernumerary teeth were able to develop attached colonies consisting of fibroblastic cells on plastic dishes (Appendix Fig. 1A). The colonies expressed different sizes and various densities. The colony-forming efficiency was 88.0 Â± 2.0 (means Â± SD, n = 5) <italic>per</italic> 1 x 10<sup>6</sup>. The frequency of colony formation was significantly increased depending on the number of plating cell densities (Appendix Fig. 1B). SNTSCs exhibited <italic>in vitro</italic> prolonged, but limited, cell proliferation (total population-doubling score: 65.4 Â± 3.2, n = 5) by population-doubling assay. Bromodeoxyuridine (BrdU) was largely incorporated into the nuclei of SNTSCs (74.1 Â± 4.0%, n = 5). Flow cytometry demonstrated that SNTSCs were negative to hematopoietic cell markers CD34, CD45, and CD14 and positive to MSC markers CD73 (99.7 Â± 0.3%), CD105 (97.5 Â± 1.7), and CD90 (99.8 Â± 0.1%) and an embryonic stem cell marker stage-specific embryonic antigen 4 (27.3 Â± 1.6%) (n = 5) (Appendix Fig. 1C). SNTSCs also expressed genes for both ES cell markers, <italic>NANOG</italic> and <italic>octamer 4</italic>, and neural crest cell markers, <italic>NOTCH1, NESTIN</italic>, and <italic>p75</italic> (Appendix Fig. 1D).</p>
<p>In dentinogenic/osteogenic conditions, the SNTSCs were capable of forming mineralized tissues and expressed odontoblast-/osteoblast-specific genes (<italic>runt-related transcription factor 2, alkaline phosphatase, osteocalcin</italic>, and <italic>dentin sialophosphoprotein</italic>) by Alizarin red staining and reverse-transcription/polymerase chain-reaction (RT-PCR) assay (Appendix Fig. 2A). Immunofluorescence showed that SNTSCs expressed neural cell markers glial fibrillary acidic protein, neurofilament M, and tubulin Î²III (Appendix Fig. 2B) and endothelial cell markers CD31 and CD34 (Appendix Fig. 2C) under neural and endothelial cell differentiation conditions, respectively.</p>
<p>Ten clonogenic CFU-F were obtained from the dental pulp tissue of a supernumerary tooth by a limited dilution method. The single-colony-derived SNTSCs displayed different population-doubling scores, various BrdU incorporation capacities, and various Alizarin-red-positive area formations (Appendix Fig. 3).</p>
</sec>
<sec id="section17-0022034513490732">
<title>Immunomodulatory Capacity of SNTSCs <italic>in vitro</italic></title>
<p>To examine the <italic>in vitro</italic> immunomodulatory effects of SNTSCs, we co-cultured SNTSCs with human PBMNCs or T-cells. SNTSCs inhibited the cell viability of PHA-stimulated human PBMNCs in an increased SNTSC ratio-dependent manner (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1A</xref>) and induced Annexin-V<sup>+</sup>7AAD<sup>+</sup> apoptotic cells of anti-CD3 antibody-activated human PBMNCs (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1B</xref>). In a Th17-cell differentiation condition, SNTSCs inhibited the differentiation of CD4<sup>+</sup>IL-17<sup>+</sup>interferon-gamma (IFNÎ³)<sup>-</sup> Th17 cells (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1C</xref>) and the secretion of IL-17 (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1C</xref>). Conversely, SNTSCs enhanced the differentiation of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cells (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1D</xref>) and IL-10 secretion (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1D</xref>) in a Treg differentiation condition. SNTSCs expressed higher immunomodulatory functions than hBMMSCs (<xref ref-type="fig" rid="fig1-0022034513490732">Fig. 1</xref>). Further studies will be necessary to examine in more detail the immunomodulatory capacities of SNTSCs, including T-cell proliferation and immune cell differentiation.</p>
<fig id="fig1-0022034513490732" position="float">
<label>Figure 1.</label>
<caption>
<p>Immunosuppressive effects of SNTSCs on human T-cells. (<bold>A</bold>) Inhibition of cell viability of PHA-activated human PBMNCs (PHA-PBMNC). (<bold>B</bold>) AnnexinV<sup>+</sup>7AAD<sup>+</sup> apoptotic cells of CD3 and anti-CD28 antibody-activated T-cells by flow cytometry. (<bold>C</bold>) Suppression of CD4<sup>+</sup>IL-17<sup>+</sup>IFNÎ³<sup>-</sup> (Th17) cell differentiation by flow cytometry and IL-17 secretion in the culture supernatants (Sup IL-17) by ELISA. T: anti-CD3 and anti-CD28 antibody-activated CD4<sup>+</sup>CD25<sup>-</sup> T-cells. (<bold>D</bold>) Induction of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cell (Treg) differentiation by flow cytometry and IL-10 secretion in the culture supernatants (Sup IL-10) by ELISA. T: anti-CD3 and anti-CD28 antibody-activated CD4<sup>+</sup>CD25<sup>-</sup> T-cells. (A-D) n = 5 for all groups. *<italic>p</italic> &lt; .05, ***<italic>p</italic> &lt; .005. The bar graph represents mean Â± SD.</p>
</caption>
<graphic xlink:href="10.1177_0022034513490732-fig1.tif"/>
</fig>
</sec>
<sec id="section18-0022034513490732">
<title>Systemic SNTSC Transplantation Improves SLE-like Disorders in MRL/<italic>lpr</italic> Mice</title>
<p>SLE patients have received allogenic 1 x 10<sup>6</sup> MSCs/kg body weight and experienced subsequent therapeutic efficacy and safety (<xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>, <xref ref-type="bibr" rid="bibr21-0022034513490732">2010</xref>; <xref ref-type="bibr" rid="bibr24-0022034513490732">Wang <italic>et al</italic>., 2013</xref>). To examine the <italic>in vivo</italic> immunomodulatory effects of SNTSCs, we preliminarily challenged 16-week-old MRL/<italic>lpr</italic> mice with 4 SNTSC doses (0.001, 0.01, 0.1, and 1.0x10<sup>6</sup>/10 g body weight) <italic>via</italic> systemic transplantation. The dose of 0.1 x 10<sup>6</sup>/10 g (10 x 10<sup>6</sup>/kg) showed the most effective therapeutic efficacy on serum anti-nuclear antigen (ANA) and urine protein in MRL/<italic>lpr</italic> mice 4 wks after transplantation (unpublished observations) and was used as the optimal cell dose in this study. The discrepancy between optimal cell doses for human and mouse recipients may relate to the differences of factors such as graft type (allogenic or xenogenic), recipient species (human or mouse), and recipient background (drug pre-treatment patients or CD95 mutation mice).</p>
<p>SNTSCs (0.1 x 10<sup>6</sup>/10 g) were systemically transplanted into 16-week-old MRL/<italic>lpr</italic> mice (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2A</xref>). SNTSC transplantation showed a significant prolongation of the shortened lifespan of MRL/<italic>lpr</italic> mice compared with that of non-transplanted MRL/<italic>lpr</italic> mice (<italic>p</italic> &lt; .005) (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2B</xref>). By the Mantel-Haenszel test, the median survival times were found to be 216, 210, and 162 days in the SNTSC-, hBMMSC-, and non-transplanted groups, respectively.</p>
<fig id="fig2-0022034513490732" position="float">
<label>Figure 2.</label>
<caption>
<p>Systemic SNTSC transplantation improves the lifespan and SLE-like disorders in MRL/<italic>lpr</italic> mice. (<bold>A</bold>) A scheme of systemic MSC transplantation into MRL/<italic>lpr</italic> mice. (<bold>B</bold>) Kaplan-Meier survival curve of MRL/<italic>lpr</italic> mice. (<bold>C</bold>) ELISA of ANA (serum ANA), anti-dsDNA IgG (serum dsDNA IgG), and anti-dsDNA IgM (serum dsDNA IgM) antibodies in the peripheral blood serum. (<bold>D</bold>) Representative images of kidneys. HE, hematoxylin and eosin staining; TC, Gomorri trichrome staining; PAS, Periodic acid-Schiff staining. IgG/DAPI: Immunofluorescence of mouse IgG. Nuclei are counterstained with 4â²,6-diamidino-2-phenylindole (DAPI). Dot-circled area, <italic>G</italic>: glomerular. Bars = 50 Âµm. (<bold>E</bold>) Levels of urine protein, serum albumin, and creatinine. (<bold>B-E</bold>) BL/6, C57BL/6 group; MRL/<italic>lpr</italic>, non-transplanted MRL/<italic>lpr</italic> group; hBMMSC, hBMMSC-transplanted MRL/<italic>lpr</italic> group; and SNTSC, SNTSC-transplanted MRL/<italic>lpr</italic> group. (B) n = 7, (C-E) n = 5 for all groups. (C, E) *<italic>p</italic> &lt; .05, **<italic>p</italic> &lt; .01, ***<italic>p</italic> &lt; .005. The bar graph represents mean Â± SD.</p>
</caption>
<graphic xlink:href="10.1177_0022034513490732-fig2.tif"/>
</fig>
<p>MRL/<italic>lpr</italic> mice at the age of 20 wks expressed over-production of ANA and anti-dsDNA IgG and IgM antibodies compared with age-matched C57BL/6 mice (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2C</xref>). Non-transplanted MRL/<italic>lpr</italic> mice at 20 wks showed typical histological glomerulonephritis, including compression of the glomerular capillary, thickness of the capillary basal membrane, and deposition of collagen and IgG in the mesangium (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2D</xref>), and biochemical glomerulonephritis, including increased urine protein and serum creatinine and reduced serum albumin (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2E</xref>) when compared with those of control wild-type C57BL/6 mice. In contrast, systemic transplantation of SNTSC significantly reduced the elevated serum levels of the autoantibodies in MRL/<italic>lpr</italic> mice at 20 wks. The SNTSC transplantation unpacked the capillary compression, reduced the hyperthickness of the basement membrane, and diminished the deposition of collagen and IgG in the glomerulus (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2D</xref>). The levels of urine protein, serum albumin, and serum creatinine were recovered after the SNTC transplantation into MRL/<italic>lpr</italic> mice (<xref ref-type="fig" rid="fig2-0022034513490732">Fig. 2E</xref>). The therapeutic effects in the SNTSC group were similar to those in the hBMMSC-transplant group (<xref ref-type="fig" rid="fig2-0022034513490732">Figs. 2C</xref>-<xref ref-type="fig" rid="fig2-0022034513490732">2E</xref>).</p>
</sec>
<sec id="section19-0022034513490732">
<title>SNTSC transplantation Suppresses Hyper-immunoreactivity of T-cells, Especially Th17 Cells, in MRL/<italic>lpr</italic> Mice</title>
<p>In 20-week-old MRL/<italic>lpr</italic> mice, CD4<sup>+</sup>IL-17<sup>+</sup>IFNÎ³<sup>-</sup> Th17 cells and IL-17 were significantly increased, and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs and IL-10 were reduced in the peripheral blood (<xref ref-type="fig" rid="fig3-0022034513490732">Figs. 3A</xref>, <xref ref-type="fig" rid="fig3-0022034513490732">3B</xref>), and the ratio of Tregs/Th17 cells was markedly decreased (<xref ref-type="fig" rid="fig3-0022034513490732">Fig. 3A</xref>) in comparison with that in the age-matched control C57BL/6 mice. Systemic transplantation of SNTSCs affected the recovery of the Treg/Th17 cell ratio, with the down-regulation of Th17 cell function and the up-regulation of Treg function. The immune efficacy of SNTSC transplantation was higher than that in the hBMMSC-transplanted group (<xref ref-type="fig" rid="fig3-0022034513490732">Fig. 3</xref>).</p>
<fig id="fig3-0022034513490732" position="float">
<label>Figure 3.</label>
<caption>
<p>SNTSC transplantation modulates peripheral Treg/Th17 cell balance in MRL/<italic>lpr</italic> mice. (<bold>A</bold>) Flow cytometry of peripheral CD4<sup>+</sup>IL-17<sup>+</sup>IFNÎ³<sup>-</sup> (Th17) cells and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cells (Tregs) and the ratio of Tregs/Th17 cells (Tregs/Th17) in MRL/<italic>lpr</italic> mice. (<bold>B</bold>) Serum levels of IL-17 and IL-10 in MRL/<italic>lpr</italic> mice by ELISA.</p>
</caption>
<graphic xlink:href="10.1177_0022034513490732-fig3.tif"/>
</fig>
</sec>
<sec id="section20-0022034513490732">
<title>Systemically Infused SNTSCs Localize to Spleen and Kidney in MRL/<italic>lpr</italic> Mice and Regulate the Local Immune Environment</title>
<p>Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled SNTSCs were intravenously injected into 16-week-old MRL/<italic>lpr</italic> mice. The high frequency of CFSE-labeled SNTSCs was observed in the spleen and kidneys, particularly in the glomeruli, one day after the transplantation (<xref ref-type="fig" rid="fig4-0022034513490732">Fig. 4A</xref>). The frequency of CFSE-labeled SNTSCs decreased gradually in both tissues from the 7th day after transplantation (<xref ref-type="fig" rid="fig4-0022034513490732">Fig. 4A</xref>). The distribution of SNTSCs was similar to that of hBMMSCs (<xref ref-type="fig" rid="fig4-0022034513490732">Fig. 4A</xref>). The levels of inflammatory cytokine IL-17 in the spleen and kidneys were significantly reduced in SNTSC- and hBMMSC-transfused MRL/<italic>lpr</italic> mice when compared with those in control MRL/<italic>lpr</italic> mice (<xref ref-type="fig" rid="fig4-0022034513490732">Fig. 4B</xref>).</p>
<fig id="fig4-0022034513490732" position="float">
<label>Figure 4.</label>
<caption>
<p>SNTSC transplantation suppresses hyper-activity of Th17 cells in MRL/<italic>lpr</italic> mice. (<bold>A</bold>) Homing of systemically infused CFSE-labeled SNTSCs (CFSE-SNTSC) and hBMMSCs (CFSE-hBMMSC) to spleen and kidney of MRL/<italic>lpr</italic> Mice after 1- (Day 1) or 7- (Day 7) day transplantation. Dot-circled area, <italic>G</italic>: glomerular. CSFE, CSFE staining images; DAPI, DAPI staining images; Merged, Merged images. Bar = 50 Âµm. (<bold>B</bold>) IL-17 levels in spleen (Spleen IL-17) and kidney (Kidney IL-17). (<bold>C</bold>) IL-17 level in the culture supernatants of splenic T-cells (Spleen-T IL-17) isolated from MRL/<italic>lpr</italic> mice. (<bold>D</bold>) Adoptive transfer of T-cells from MRL/<italic>lpr</italic> mice. A scheme of adoptive transfer of Spleen-T into SCID mice. Kaplan-Meier survival curve of SCID mice. (A-C) n = 5. (D) n = 7 for all groups. (B) BL/6, C57BL/6 group; MRL/<italic>lpr</italic>, non-transplanted group; hBMMSC, hBMMSC-transplanted group; and SNTSC, SNTSC-transplanted group. (C) T-MRL/<italic>lpr</italic>, T-hBMMSC, T-SNTSC: Spleen-T from non-transplanted, hBMMSC-transplanted, and SNTSC-transplanted groups, respectively. (D) Control, T-MRL/<italic>lpr</italic>-T, T-hBMMSC-T, T-SNTSC-T: non-, T-MRL/<italic>lpr</italic>-, T-hBMMSC-, and T-SNTSC-adaptive transferred groups, respectively. (B, C) *<italic>p</italic> &lt; .05, **<italic>p</italic> &lt; .01, ***<italic>p</italic> &lt; .005. The bar graph represents mean Â± SD.</p>
</caption>
<graphic xlink:href="10.1177_0022034513490732-fig4.tif"/>
</fig>
<p>To analyze T-cell toxicity in MRL/lpr mice, we isolated splenic T-cells from non-, SNTSC-, and hBMMSC-transplanted MRL/<italic>lpr</italic> mice, termed T-MRL/<italic>lpr</italic>, T-SNTSC, and T-hBMMSC, respectively, and stimulated them for 3 days with anti-CD3 and anti-CD28 antibodies. Supernatant levels of IL-17 of T-SNTSC and T-hBMMSC cultures were markedly lower than those of T-MRL/<italic>lpr</italic> (<xref ref-type="fig" rid="fig4-0022034513490732">Figure 4C</xref>). We transplanted these T-cells into SCID mice (<xref ref-type="bibr" rid="bibr6-0022034513490732">Fraziano <italic>et al</italic>., 1994</xref>) and assessed <italic>in vivo</italic> survival damage. The transplantation of T-SNTSC- and T-hBMMSC extended the shortened lifespan of T-MRL/<italic>lpr</italic>âtransplanted mice (<xref ref-type="fig" rid="fig4-0022034513490732">Fig. 4D</xref>). The median survival time was significantly prolonged in T-SNTSC- (37 days, <italic>p</italic> &lt; .005) and T-hBMMSC- (36 days, <italic>p</italic> &lt; .005) transplanted groups when compared with the T-MRL/<italic>lpr</italic>-transplanted group (10 days).</p>
</sec>
</sec>
<sec id="section21-0022034513490732" sec-type="discussion">
<title>Discussion</title>
<p>To date, hBMMSC therapy has enjoyed substantial success in regenerative medicine (<xref ref-type="bibr" rid="bibr11-0022034513490732">Le Blanc <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>, <xref ref-type="bibr" rid="bibr21-0022034513490732">2010</xref>; <xref ref-type="bibr" rid="bibr24-0022034513490732">Wang <italic>et al</italic>., 2013</xref>). In contrast, human bone marrow has been shown to have not only invasive harvesting problems but also donor age-related problems, associated with harvestable stem cell numbers, <italic>ex vivo</italic> expansion, and potential (<xref ref-type="bibr" rid="bibr19-0022034513490732">Stolzing <italic>et al</italic>., 2008</xref>). These problems represent significant difficulties for the utilization of hBMMSCs in regenerative medicine. Various MSC candidates have been identified from umbilical cord blood (<xref ref-type="bibr" rid="bibr5-0022034513490732">Erices <italic>et al</italic>., 2000</xref>) and adipose tissues (<xref ref-type="bibr" rid="bibr30-0022034513490732">Zuk <italic>et al</italic>., 2001</xref>). Present and current studies (<xref ref-type="bibr" rid="bibr9-0022034513490732">Huang <italic>et al</italic>., 2008</xref>) demonstrated the existence of multipotential MSCs in the dental pulp of supernumerary teeth. Since supernumerary teeth cause esthetic, oral hygiene, and masticatory problems, they are usually extracted and discarded clinically. Therefore, supernumerary teeth might be a promising stem cell source with minimal ethical issues in regenerative medicine.</p>
<p>SLE has been known to be a typically fatal autoimmune disease with autoantibody-caused multiple organ disorders including lupus nephritis. Allogenic transplantation of hBMMSCs and human umbilical-cord-derived MSCs (UCMSCs) has shown successful therapeutic efficacy in refractory SLE patients (<xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>, <xref ref-type="bibr" rid="bibr21-0022034513490732">2010</xref>; <xref ref-type="bibr" rid="bibr24-0022034513490732">Wang <italic>et al</italic>., 2013</xref>). MRL<italic>/lpr</italic> mice show SLE-like disorders, including shortened lifespan, abundant autoantibodies, glomerulonephritis, and a breakdown of self-tolerance similar to that of human SLE patients (<xref ref-type="bibr" rid="bibr22-0022034513490732">Theofilopoulos and Dixon, 1985</xref>). Currently, systemic transplantation of human MSCs, including BMMSCs, UCMSCs, and SHED, improves SLE-like disorders in MRL/<italic>lpr</italic> mice (<xref ref-type="bibr" rid="bibr29-0022034513490732">Zhou <italic>et al</italic>., 2008</xref>; <xref ref-type="bibr" rid="bibr8-0022034513490732">Gu <italic>et al</italic>., 2010</xref>; <xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>), indicating that the xenogenic transplantation of human MSCs into MRL/<italic>lpr</italic> mice might be a novel discovery of a new cell-based therapeutic approach for human SLE. In this study, systemically transplanted SNTSCs reduced hyperproduction of autoantibodies and recovered renal dysfunction in MRL/<italic>lpr</italic> mice. Therefore, analysis of these data suggests that SNTSCs might have a therapeutic benefit for SLE disorders.</p>
<p>The immunoregulatory mechanisms of MSCs are associated with both a paracrine effect of MSC-producing factors [indoleamine 2,3-dioxygenase, IL-10, transforming growth factor-Î²1, and tumor necrosis factor-Î± (TNFÎ±)-stimulated gene/protein 6, etc.] and a cell-contact-dependent mechanism (Jagged1/Notch1, Fas/Fas ligand and programmed death-1/ programmed death-ligand 1 pathways) (<xref ref-type="bibr" rid="bibr3-0022034513490732">DelaRosa <italic>et al</italic>., 2012</xref>; <xref ref-type="bibr" rid="bibr4-0022034513490732">English, 2013</xref>). MSCs also induce Tregs and inhibit Th17 cells to display immune tolerance by shifting the balance of Tregs /Th17 cells (<xref ref-type="bibr" rid="bibr20-0022034513490732">Sun <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr26-0022034513490732">Yamaza <italic>et al</italic>., 2010</xref>). The immunoregulatory properties of MSCs are primed by IFNÎ³, IL-1Î², and TNFÎ± released from activated immune cells (<xref ref-type="bibr" rid="bibr10-0022034513490732">Krampera <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="bibr14-0022034513490732">Prasanna <italic>et al</italic>., 2010</xref>). The present systemic transplantation experiment, as well as these co-culture experiments, demonstrated that transplanted SNTSCs regulate the disturbed immune system in MRL/<italic>lpr</italic> mice. In addition, the present adoptive transfer experiment supports <italic>in vivo</italic> immunosuppressive effects of systemically infused SNTSCs on hyper-activated T-cells in MRL/<italic>lpr</italic> mice. Infused SNTSCs homed in on local lesions, including the kidney and spleen of MRL/<italic>lpr</italic> mice, might control systemic and regional immune conditions through local inflammatory environments. However, the <italic>in vivo</italic> detailed mechanism of SNTSC-mediated immunomodulation is not fully understood. Therefore, further studies will be necessary to elucidate the detailed immunoregulatory mechanisms of SNTSC-based immunotherapy.</p>
<p>In conclusion, the present study evaluates, at least partially, the <italic>in vitro</italic> immunomodulatory functions of SNTSCs on T-cells. Moreover, systemic SNTSC transplantation ameliorates SLE disorders <italic>via</italic> suppressing hyper-immune reaction in human SLE-like model MRL/<italic>lpr</italic> mice. Analysis of these data suggests that SNTSCs offer an accessible and executable MSC source for cell-based immune therapies for human autoimmune diseases.</p>
</sec>
</body>
<back>
<ack>
<p>Y.M. and H.Y., for collection and assembly of data, data analysis and interpretation; K.A., L.M., Y.H., K.N., and Y.T., for data analysis and interpretation; T.K. and S.S., for conception and design, data analysis and interpretation; and T.Y., for collection and assembly of data, data analysis and interpretation, conception and design, data analysis and interpretation, and manuscript writing.</p>
</ack>
<fn-group>
<fn fn-type="supported-by">
<p>This work was supported by grants-in-aid for Scientific Research (B) (No. 25293405 to TY), Scientific Research (B) (No. 25463187 to HY), Challenging Exploratory Research Project (No. 24659815 to TY), and Young Scientists (B) (No. 20790260 to H.Y.) from the Japan Society for Promotion of Science and by grants from the <grant-sponsor>National Institute of Dental and Craniofacial Research, National Institutes of Health, US Department of Health and Human Services</grant-sponsor><?release-delay 12|0?> (<grant-num>R01DE17449</grant-num> and <grant-num>R01DE019156</grant-num> to S.S.). We are grateful to Dr. Keiji Masuda (Department of Pediatric Dentistry, Kyushu University Hospital) for his clinical support.</p></fn>
<fn fn-type="conflict">
<p>The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="supplementary-material">
<p>A supplemental appendix to this article is published electronically only at <ext-link ext-link-type="uri" xlink:href="http://jdr.sagepub.com/supplemental">http://jdr.sagepub.com/supplemental</ext-link>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bianco</surname><given-names>P</given-names></name>
<name><surname>Riminucci</surname><given-names>M</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name>
<name><surname>Robey</surname><given-names>PG</given-names></name>
</person-group> (<year>2001</year>). <article-title>Bone marrow stromal stem cells: nature, biology, and potential applications</article-title>. <source>Stem Cells</source> <volume>19</volume>:<fpage>180</fpage>-<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr2-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corcione</surname><given-names>A</given-names></name>
<name><surname>Benvenuto</surname><given-names>F</given-names></name>
<name><surname>Ferretti</surname><given-names>E</given-names></name>
<name><surname>Giunti</surname><given-names>D</given-names></name>
<name><surname>Cappiello</surname><given-names>V</given-names></name>
<name><surname>Cazzanti</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2006</year>). <article-title>Human mesenchymal stem cells modulate B-cell functions</article-title>. <source>Blood</source> <volume>107</volume>:<fpage>367</fpage>-<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr3-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DelaRosa</surname><given-names>O</given-names></name>
<name><surname>Dalemans</surname><given-names>W</given-names></name>
<name><surname>Lombardo</surname><given-names>E</given-names></name>
</person-group> (<year>2012</year>). <article-title>Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases</article-title>. <source>Curr Opin Biotechnol</source> <volume>23</volume>:<fpage>978</fpage>-<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr4-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>English</surname><given-names>K</given-names></name>
</person-group> (<year>2013</year>). <article-title>Mechanism of mesenchymal stromal cell immunomodulation</article-title>. <source>Immunol Cell Biol</source> <volume>91</volume>:<fpage>19</fpage>-<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr5-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erices</surname><given-names>A</given-names></name>
<name><surname>Conget</surname><given-names>P</given-names></name>
<name><surname>Minguell</surname><given-names>JJ</given-names></name>
</person-group> (<year>2000</year>). <article-title>Mesenchymal progenitor cells in human umbilical cord blood</article-title>. <source>Br J Haematol</source> <volume>109</volume>:<fpage>235</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr6-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraziano</surname><given-names>M</given-names></name>
<name><surname>Montesano</surname><given-names>C</given-names></name>
<name><surname>Sammarco</surname><given-names>I</given-names></name>
<name><surname>di Cesare</surname><given-names>S</given-names></name>
<name><surname>Caroleo</surname><given-names>MC</given-names></name>
<name><surname>Mattei</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>1994</year>). <article-title>Induction of graft versus host disease in SCID mice by MRL/<italic>lpr</italic> cell transfer</article-title>. <source>Clin Immunol Immunopathol</source> <volume>71</volume>:<fpage>265</fpage>-<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr7-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gronthos</surname><given-names>S</given-names></name>
<name><surname>Mankani</surname><given-names>M</given-names></name>
<name><surname>Brahim</surname><given-names>J</given-names></name>
<name><surname>Robey</surname><given-names>PG</given-names></name>
<name><surname>Shi</surname><given-names>S</given-names></name>
</person-group> (<year>2000</year>). <article-title>Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>97</volume>:<fpage>13625</fpage>-<lpage>13630</lpage>.</citation>
</ref>
<ref id="bibr8-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gu</surname><given-names>Z</given-names></name>
<name><surname>Akiyama</surname><given-names>K</given-names></name>
<name><surname>Ma</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Yao</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2010</year>). <article-title>Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice</article-title>. <source>Lupus</source> <volume>19</volume>:<fpage>1502</fpage>-<lpage>1514</lpage>.</citation>
</ref>
<ref id="bibr9-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>AH</given-names></name>
<name><surname>Chen</surname><given-names>YK</given-names></name>
<name><surname>Lin</surname><given-names>LM</given-names></name>
<name><surname>Shieh</surname><given-names>TY</given-names></name>
<name><surname>Chan</surname><given-names>AW</given-names></name>
</person-group> (<year>2008</year>). <article-title>Isolation and characterization of dental pulp stem cells from a supernumerary tooth</article-title>. <source>J Oral Pathol Med</source> <volume>37</volume>:<fpage>571</fpage>-<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr10-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krampera</surname><given-names>M</given-names></name>
<name><surname>Cosmi</surname><given-names>L</given-names></name>
<name><surname>Angeli</surname><given-names>R</given-names></name>
<name><surname>Pasini</surname><given-names>A</given-names></name>
<name><surname>Liotta</surname><given-names>F</given-names></name>
<name><surname>Andreini</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2006</year>). <article-title>Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells</article-title>. <source>Stem Cells</source> <volume>24</volume>:<fpage>386</fpage>-<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr11-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Blanc</surname><given-names>K</given-names></name>
<name><surname>Rasmusson</surname><given-names>I</given-names></name>
<name><surname>Sundberg</surname><given-names>B</given-names></name>
<name><surname>GÃ¶therstrÃ¶m</surname><given-names>C</given-names></name>
<name><surname>Hassan</surname><given-names>M</given-names></name>
<name><surname>Uzunel</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2004</year>). <article-title>Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells</article-title>. <source>Lancet</source> <volume>363</volume>:<fpage>1439</fpage>-<lpage>1441</lpage>.</citation>
</ref>
<ref id="bibr12-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ma</surname><given-names>L</given-names></name>
<name><surname>Makino</surname><given-names>Y</given-names></name>
<name><surname>Yamaza</surname><given-names>H</given-names></name>
<name><surname>Akiyama</surname><given-names>K</given-names></name>
<name><surname>Hoshino</surname><given-names>Y</given-names></name>
<name><surname>Song</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2012</year>). <article-title>Cryopreserved dental pulp tissues of exfoliated deciduous teeth is [sic] a feasible stem cell resource for regenerative medicine</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e51777</fpage>.</citation>
</ref>
<ref id="bibr13-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miura</surname><given-names>M</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>M</given-names></name>
<name><surname>Lu</surname><given-names>B</given-names></name>
<name><surname>Fisher</surname><given-names>LW</given-names></name>
<name><surname>Robey</surname><given-names>PG</given-names></name><etal/>
</person-group>. (<year>2003</year>). <article-title>SHED: stem cells from human exfoliated deciduous teeth</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>100</volume>:<fpage>5807</fpage>-<lpage>5812</lpage>.</citation>
</ref>
<ref id="bibr14-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prasanna</surname><given-names>SJ</given-names></name>
<name><surname>Gopalakrishnan</surname><given-names>D</given-names></name>
<name><surname>Shankar</surname><given-names>SR</given-names></name>
<name><surname>Vasandan</surname><given-names>AB</given-names></name>
</person-group> (<year>2010</year>). <article-title>Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially</article-title>. <source>PLoS One</source> <volume>5</volume>:<fpage>e9016</fpage>.</citation>
</ref>
<ref id="bibr15-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramasamy</surname><given-names>R</given-names></name>
<name><surname>Fazekasova</surname><given-names>H</given-names></name>
<name><surname>Lam</surname><given-names>EW</given-names></name>
<name><surname>Soeiro</surname><given-names>I</given-names></name>
<name><surname>Lombardi</surname><given-names>G</given-names></name>
<name><surname>Dazzi</surname><given-names>F</given-names></name>
</person-group> (<year>2007</year>). <article-title>Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle</article-title>. <source>Transplantation</source> <volume>83</volume>:<fpage>71</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr16-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seo</surname><given-names>BM</given-names></name>
<name><surname>Miura</surname><given-names>M</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name>
<name><surname>Bartold</surname><given-names>PM</given-names></name>
<name><surname>Batouli</surname><given-names>S</given-names></name>
<name><surname>Brahim</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2004</year>). <article-title>Investigation of multipotent postnatal stem cells from human periodontal ligament</article-title>. <source>Lancet</source> <volume>364</volume>:<fpage>149</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr17-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sonoyama</surname><given-names>W</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Fang</surname><given-names>D</given-names></name>
<name><surname>Yamaza</surname><given-names>T</given-names></name>
<name><surname>Seo</surname><given-names>BM</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2006</year>). <article-title>Mesenchymal stem cell-mediated functional tooth regeneration in swine</article-title>. <source>PLoS One</source> <volume>1</volume>:<fpage>e79</fpage>.</citation>
</ref>
<ref id="bibr18-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spaggiari</surname><given-names>GM</given-names></name>
<name><surname>Capobianco</surname><given-names>A</given-names></name>
<name><surname>Becchetti</surname><given-names>S</given-names></name>
<name><surname>Mingari</surname><given-names>MC</given-names></name>
<name><surname>Moretta</surname><given-names>L</given-names></name>
</person-group> (<year>2006</year>). <article-title>Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation</article-title>. <source>Blood</source> <volume>107</volume>:<fpage>1484</fpage>-<lpage>1490</lpage>.</citation>
</ref>
<ref id="bibr19-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stolzing</surname><given-names>A</given-names></name>
<name><surname>Jones</surname><given-names>E</given-names></name>
<name><surname>McGonagle</surname><given-names>D</given-names></name>
<name><surname>Scutt</surname><given-names>A</given-names></name>
</person-group> (<year>2008</year>). <article-title>Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies</article-title>. <source>Mech Ageing Dev</source> <volume>129</volume>:<fpage>163</fpage>-<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr20-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Akiyama</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Yamaza</surname><given-names>T</given-names></name>
<name><surname>Hou</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2009</year>). <article-title>Mesenchymal stem cell transplantation reverses multi-organ dysfunction in systemic lupus erythematosus mice and humans</article-title>. <source>Stem Cells</source> <volume>27</volume>:<fpage>1421</fpage>-<lpage>1432</lpage>.</citation>
</ref>
<ref id="bibr21-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Liang</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2010</year>). <article-title>Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>:<fpage>2467</fpage>-<lpage>2475</lpage>.</citation>
</ref>
<ref id="bibr22-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Theofilopoulos</surname><given-names>AN</given-names></name>
<name><surname>Dixon</surname><given-names>FJ</given-names></name>
</person-group> (<year>1985</year>). <article-title>Murine models of systemic lupus erythematosus</article-title>. <source>Adv Immunol</source> <volume>37</volume>:<fpage>269</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr23-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wada</surname><given-names>N</given-names></name>
<name><surname>Menicanin</surname><given-names>D</given-names></name>
<name><surname>Shi</surname><given-names>S</given-names></name>
<name><surname>Bartold</surname><given-names>PM</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name>
</person-group> (<year>2009</year>). <article-title>Immunomodulatory properties of human periodontal ligament cells</article-title>. <source>J Cell Physiol</source> <volume>219</volume>:<fpage>667</fpage>-<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr24-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Liang</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2013</year>). <article-title>Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience</article-title>. <source>Cell Transplant</source> [Epub ahead of print 10/31/2012] (in press).</citation>
</ref>
<ref id="bibr25-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaza</surname><given-names>T</given-names></name>
<name><surname>Miura</surname><given-names>Y</given-names></name>
<name><surname>Akiyama</surname><given-names>K</given-names></name>
<name><surname>Bi</surname><given-names>Y</given-names></name>
<name><surname>Sonoyama</surname><given-names>W</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2009</year>). <article-title>Mesenchymal stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice</article-title>. <source>Blood</source> <volume>113</volume>:<fpage>2595</fpage>-<lpage>2604</lpage>.</citation>
</ref>
<ref id="bibr26-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaza</surname><given-names>T</given-names></name>
<name><surname>Akiyama</surname><given-names>K</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Gronthos</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2010</year>). <article-title>Immunomodulatory properties of stem cells from human exfoliated deciduous teeth</article-title>. <source>Stem Cell Res Ther</source> <volume>1</volume>:<fpage>5</fpage>.</citation>
</ref>
<ref id="bibr27-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>S</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Uyanne</surname><given-names>J</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>S</given-names></name>
<name><surname>Le</surname><given-names>AD</given-names></name>
</person-group> (<year>2009</year>). <article-title>Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis</article-title>. <source>J Immunol</source> <volume>183</volume>:<fpage>7787</fpage>-<lpage>7798</lpage>.</citation>
</ref>
<ref id="bibr28-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>S</given-names></name>
</person-group> (<year>2012</year>). <article-title>Fas ligand regulates the immunomodulatory properties of dental pulp stem cells</article-title>. <source>J Dent Res</source> <volume>91</volume>:<fpage>948</fpage>-<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr29-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Jin</surname><given-names>O</given-names></name>
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Yao</surname><given-names>G</given-names></name>
<name><surname>Hou</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2008</year>). <article-title>Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice</article-title>. <source>Cell Mol Immunol</source> <volume>5</volume>:<fpage>417</fpage>-<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr30-0022034513490732">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zuk</surname><given-names>PA</given-names></name>
<name><surname>Zhu</surname><given-names>M</given-names></name>
<name><surname>Mizuno</surname><given-names>H</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<name><surname>Futrell</surname><given-names>JW</given-names></name>
<name><surname>Katz</surname><given-names>AJ</given-names></name><etal/>
</person-group>. (<year>2001</year>). <article-title>Multilineage cells from human adipose tissue: implications for cell-based therapies</article-title>. <source>Tissue Eng</source> <volume>7</volume>:<fpage>211</fpage>-<lpage>228</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>